These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 37469024)

  • 1. Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial.
    Chen S; Shen W; Liu Y; Dong Q; Shi Y
    Chin Med J (Engl); 2023 Jul; 136(14):1690-1698. PubMed ID: 37469024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of triple therapy containing berberine hydrochloride, amoxicillin, and rabeprazole in the eradication of Helicobacter pylori.
    Chen XX; Chen YX; Bi HX; Zhao X; Zhang LF; Liu JY; Shi YQ
    J Dig Dis; 2022 Oct; 23(10):568-576. PubMed ID: 36415112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China.
    Xie Y; Zhu Z; Wang J; Zhang L; Zhang Z; Lu H; Zeng Z; Chen S; Liu D; Lv N;
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vonoprazan Dual or Triple Therapy Versus Bismuth-Quadruple Therapy as First-Line Therapy for Helicobacter pylori Infection: A Three-Arm, Randomized Clinical Trial.
    Cheung KS; Lyu T; Deng Z; Han S; Ni L; Wu J; Tan JT; Qin J; Ng HY; Leung WK; Seto WK
    Helicobacter; 2024; 29(5):e13133. PubMed ID: 39244723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quadruple therapy with vonoprazan 20 mg daily as a first-line treatment for Helicobacter pylori infection: A single-center, open-label, noninferiority, randomized controlled trial.
    Lu L; Wang Y; Ye J; Han Y; Lou G; Li Y; Yan H; Du Q
    Helicobacter; 2023 Feb; 28(1):e12940. PubMed ID: 36458325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial.
    Zhang D; Ke L; Ni Z; Chen Y; Zhang LH; Zhu SH; Li CJ; Shang L; Liang J; Shi YQ
    Medicine (Baltimore); 2017 Aug; 96(32):e7697. PubMed ID: 28796053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
    Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
    World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy.
    Qian HS; Li WJ; Dang YN; Li LR; Xu XB; Yuan L; Zhang WF; Yang Z; Gao X; Zhang M; Li X; Zhang GX
    Am J Gastroenterol; 2023 Apr; 118(4):627-634. PubMed ID: 36729890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study.
    Han YY; Zhou L; Hu YL; Ding XW; Long H; Liu F; Xu M; Zhang ZY; Li SL; Wang QY; Su CX; Chen Y; Chen J; Lin Y; Li PY
    J Gastroenterol; 2023 Dec; 58(12):1167-1177. PubMed ID: 37777987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vonoprazan on the Eradication of Helicobacter pylori Infection.
    Huang J; Lin Y
    Turk J Gastroenterol; 2023 Mar; 34(3):221-226. PubMed ID: 36511603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults.
    Pan X; Li Y; Qiu Y; Tang Q; Qian B; Yao L; Shi R; Zhang G
    Clin Ther; 2010 Nov; 32(12):2003-11. PubMed ID: 21118735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of vonoprazan and amoxicillin as the first-line Helicobacter pylori eradication therapy: a multicenter, prospective, randomized, parallel-controlled study.
    Peng X; Chen HW; Wan Y; Su PZ; Yu J; Liu JJ; Lu Y; Zhang M; Yao JY; Zhi M
    Clin Exp Med; 2023 Nov; 23(7):4011-4019. PubMed ID: 37115412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of 10 and 14 days of antofloxacin-based versus 14 days of clarithromycin-based bismuth quadruple therapy for Helicobacter pylori eradication: A randomized trial.
    He XJ; Wang XL; Huang XY; Li DZ; Liu G; Wang W; Li DL
    Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102052. PubMed ID: 36400418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth-containing quadruple therapy for Helicobacter pylori eradication in central China: A single-center, prospective, open-label, randomized-controlled trial.
    Shao QQ; Yu XC; Yu M; Ma J; Zhao JB; Yuan L; Qi YB; Hu RB; Wei PR; Xiao W; Lan L; Jia BL; Zhang LZ; Ding SZ
    Helicobacter; 2022 Apr; 27(2):e12876. PubMed ID: 35150597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vonoprazan is noninferior to proton pump inhibitors in bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: A propensity score matching analysis.
    Wang J; Li YY; Lin MJ; Liu J; Lin BS; Ding YM; Wan M; Zhang WL; Kong QZ; Wang ST; Mu YJ; Duan M; Han ZX; Zuo XL; Li YQ
    J Dig Dis; 2023 Jan; 24(1):19-27. PubMed ID: 36960538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of vonoprazan-based dual therapy with vonoprazan-based bismuth quadruple therapy for treatment-naive patients with Helicobacter pylori infection: A propensity score matching analysis.
    Liu Z; Chen X; Sun DJ; Zhao WW; Kou L; Zheng WW; Hao JR; Gao FY
    Medicine (Baltimore); 2024 Mar; 103(10):e37476. PubMed ID: 38457567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eradication rates of Helicobacter pylori in treatment-naive patients following 14-day vonoprazan-amoxicillin dual therapy: A multicenter randomized controlled trial in China.
    Hu J; Mei H; Su NY; Sun WJ; Zhang DK; Fan LL; He P; Pan J; Wang XW; Zou PY; Liu YX; Guo Y; Lan CH
    Helicobacter; 2023 Aug; 28(4):e12970. PubMed ID: 37160689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ten-Day Vonoprazan-Amoxicillin Dual Therapy vs Standard 14-Day Bismuth-Based Quadruple Therapy for First-Line Helicobacter pylori Eradication: A Multicenter Randomized Clinical Trial.
    Yan TL; Wang JH; He XJ; Zhu YB; Lu LJ; Wang YJ; Wang ZW; Gao JG; Xu CF; Ma H; Luan SM; Li L; Chen Y
    Am J Gastroenterol; 2024 Apr; 119(4):655-661. PubMed ID: 37975609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for
    Bang CS; Lim H; Jeong HM; Shin WG; Choi JH; Soh JS; Kang HS; Yang YJ; Hong JT; Shin SP; Suk KT; Lee JJ; Baik GH; Kim DJ
    Gut Microbes; 2020 Sep; 11(5):1314-1323. PubMed ID: 32362221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fourteen-day vonoprazan-based bismuth quadruple therapy for H. pylori eradication in an area with high clarithromycin and levofloxacin resistance: a prospective randomized study (VQ-HP trial).
    Tungtrongchitr N; Bongkotvirawan P; Ratana-Amornpin S; Siramolpiwat S; Eiamsitrakoon T; Gamnarai P; Wongcha-Um A; Yamaoka Y; Pawa KK; Vilaichone RK
    Sci Rep; 2024 Apr; 14(1):8986. PubMed ID: 38637591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.